Human monoclonal autoantibodies to ADAMTS13 and uses thereof
AssigneeThe Trustees of the University of Pennsylvania
InventorsDonald L. Siegel, Stephen Kacir, Eric Ostertag, X. Long Zheng
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods of use of anti-ADAMTS13 autoantibodies and fragments thereof. In one aspect, the invention includes a composition comprising an isolated anti-ADAMTS13 autoantibody or fragment thereof. In other aspects, methods are described for generating an in vivo model of thrombotic thrombocytopenic purpura (TTP) comprising introducing at least one anti-ADAMTS13 autoantibody or fragment thereof into a model organism and identifying an anti-autoimmune reagent for treating TTP.
Claims17
A composition comprising an anti-ADAMTS13 autoantibody comprising a single chain variable fragment (scFv) and pharmaceutically acceptable carrier,
- wherein the autoantibody comprises (i) a heavy chain variable region comprising three complementarity determining regions of a heavy chain and (ii) a light chain variable region comprising three complementarity determining regions of a light chain,
- wherein the heavy and light chains respectively comprise the amino acid sequences shown in SEQ ID NOs:
- 46 and 142;
- 47 and 143;
- 48 and 144;
- 49 and 145;
- 50 and 146;
- 51 and 147;
- 52 and 148;
- 53 and 149;
- 54 and 150;
- 55 and 151;
- 56 and 152;
- 57 and 154;
- 58 and 155;
- 59 and 156;
- 60 and 157;
- 61 and 158;
- 62 and 159;
- 63 and 160;
- 64 and 161;
- 65 and 162;
- 66 and 163;
- 67 and 164;
- 68 and 165;
- 69 and 166;
- 70 and 167;
- 71 and 168;
- 72 and 170;
- 73 and 171;
- 74 and 172;
- 75 and 173;
- 76 and 174;
- 77 and 175;
- 78 and 176;
- 79 and 177;
- 80 and 179;
- 81 and 180;
- 82 and 181;
- 83 and 183;
- 84 and 184;
- 85 and 185;
- 86 and 188;
- 87 and 189;
- 88 and 190;
- 89 and 191;
- and 90 and 192.
Dependencies are inferred from the claim text.